Suppr超能文献

研究 MDR1 过表达细胞系,以利用体外外排活性为脑分布推导定量预测方法。

Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.

机构信息

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.

Drug Metabolism and Pharmacokinetics Research Laboratories, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, Japan.

出版信息

Eur J Pharm Sci. 2020 Jan 15;142:105119. doi: 10.1016/j.ejps.2019.105119. Epub 2019 Nov 1.

Abstract

MDR1-overexpressing Lilly Laboratories cell porcine kidney 1 cells (LLC-PK1-MDR1) and Madin-Darby canine kidney cells (MDCK-MDR1) are widely used in drug discovery to evaluate the in vivo relevance of MDR1-mediated efflux. However, as the in vitro efflux ratio (ER) of these cell lines are variable among research facilities, the in vitro ER of these cell lines that would affect quantitative predictivity of brain disposition has not been fully clarified. The aim of this study was to examine the effect of ER on the quantitative predictivity of brain disposition toward compounds with MDR1 and/or breast cancer resistant protein (BCRP) liabilities. Test compounds including internal molecules and five typical substrates of MDR1 and/or BCRP were assessed via an in vitro transporter assay to determine the corrected flux ratio (CFR) and an in vivo animal study using wild-type (WT) and Mdr1a (-/-)/Bcrp(-/-) (dual KO) rats. To assess the in vivo ER for MDR1, the two cell lines LLC-PK1-MDR1 and MDCK-MDR1 were used. After intravenously administering 29 test compounds to rats, the K ratio (ratio of K to K), which is considered to be the unbound plasma-to-brain ratio (K) that does not require correction for protein binding in both plasma and brain, was determined by measuring their concentrations in the plasma and brain. The K ratio of these compounds was predicted by fitting scaling factor that was extrapolated from the in vitro to in vivo ER for MDR1 and BCRP, defined as α and β, respectively. K ratio values of 83% and 68% of compounds were predicted by using MDCK-MDR1 and LLC-PK1-MDR1, respectively, within a 2-fold range of the actual corresponding values. The α predicted from CFRs of MDCK-MDR1 was 47-fold smaller than that of LLC-PK1-MDR1; however, a dramatic change in β was not observed. This result appears to be consistent with the data of in vitro transport activity of MDR1, which was estimated to be ~28-fold higher in MDCK-MDR1 than in LLC-PK1-MDR1 by correlation analysis with CFR. Through this study, we revealed that 1) brain disposition in rats was well-predicted by considering the in vitro efflux activities for both MDR1 and BCRP, and 2) MDCK-MDR1 was the superior cell line for the quantitative prediction of brain disposition.

摘要

多药耐药蛋白 1 过度表达的礼来实验室猪肾 1 细胞(LLC-PK1-MDR1)和犬肾细胞(MDCK-MDR1)广泛用于药物发现,以评估多药耐药蛋白 1 介导的外排的体内相关性。然而,由于这些细胞系的体外外排比(ER)在不同的研究机构之间存在差异,因此影响脑分布定量预测能力的这些细胞系的体外 ER 尚未完全阐明。本研究旨在研究 ER 对具有多药耐药蛋白 1 和/或乳腺癌耐药蛋白(BCRP)缺陷的化合物的脑分布定量预测能力的影响。通过体外转运测定评估包括内部分子和五种典型 MDR1 和/或 BCRP 底物的测试化合物,以确定校正通量比(CFR)和使用野生型(WT)和 Mdr1a(-/-)/Bcrp(-/-)(双 KO)大鼠的体内动物研究。为了评估 MDR1 的体内 ER,使用了 LLC-PK1-MDR1 和 MDCK-MDR1 两种细胞系。在将 29 种测试化合物静脉注射给大鼠后,通过测量其在血浆和大脑中的浓度,确定了 K 比(K 与 K 的比值),这被认为是不需要校正血浆和大脑中蛋白质结合的未结合血浆与脑比(K)。这些化合物的 K 比通过拟合从体外到 MDR1 和 BCRP 的体内 ER 的外推的缩放因子来预测,分别定义为α和β。使用 MDCK-MDR1 和 LLC-PK1-MDR1 分别预测了 83%和 68%的化合物在实际相应值的 2 倍范围内。从 MDCK-MDR1 的 CFR 预测的α比 LLC-PK1-MDR1 小 47 倍;然而,β没有观察到明显的变化。这一结果似乎与通过与 CFR 的相关性分析估计 MDCK-MDR1 中的 MDR1 体外转运活性高约 28 倍的数据一致。通过这项研究,我们揭示了 1)通过考虑多药耐药蛋白 1 和 BCRP 的体外外排活性,可以很好地预测大鼠的脑分布,2)MDCK-MDR1 是定量预测脑分布的更佳细胞系。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验